Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration

BACKGROUND: Camrelizumab plus apatinib shows encouraging antitumor activity and acceptable toxicity in chemotherapy-pretreated patients with advanced non-small cell lung cancer (NSCLC); however, clinical benefits from this combination regimen in NSCLC patients with EGFR mutations or ALK rearrangemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Guanghui, Ni, Jian, Wang, Yina, Ren, Shengxiang, Liu, Zhihua, Chen, Gongyan, Gu, Kangsheng, Zang, Aimin, Zhao, Jun, Guo, Renhua, He, Jianxing, Lin, Xiaoyan, Pan, Yueyin, Ma, Zhiyong, Wang, Zhehai, Fan, Min, Liu, Yunpeng, Cang, Shundong, Yang, Xinfeng, Li, Weixia, Wang, Quanren, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271438/
https://www.ncbi.nlm.nih.gov/pubmed/35832447
http://dx.doi.org/10.21037/tlcr-22-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271438/
https://www.ncbi.nlm.nih.gov/pubmed/35832447
http://dx.doi.org/10.21037/tlcr-22-22

Ejemplares similares